佰金生命科学：延迟刊发2025年度业绩及暂停买卖 金十数据6月25日讯，佰金生命科学(01466.HK)公告，由于附属公司管理层变更后的交接过程较预期耗 时更长，且公司于本周初方全面控制附属公司的运营，故截至2025年3月31日止年度之年度业绩将延迟 刊发。核数师及公司需要更多时间以编制2025年度业绩。预计2025年度业绩将于2025年7月25日前刊 发。根据上市规则第13.5条，若发行人未能根据上市规则之规定刊发定期财务资料，联交所通常会要求 暂停买卖发行人之证券，而暂停买卖通常会持续至发行人刊发载有必要财务资料之公告为止。倘公司未 能于2025年6月30日或之前向股东公布2025年度业绩，预期公司股份将于2025年7月2日上午9时正起于联 交所暂停买卖，以待刊发2025年度业绩公告。 ...

Shares of GeneDx Holdings (WGS -38.27%) were plunging 42.9% as of 11:21 a.m. ET on Wednesday. The steep decline came after the genetic diagnostics company announced its 2025 first-quarter earnings before the market opened.GeneDx reported Q1 revenue of $87.1 million, up 42% year over year. This result was well above the consensus Wall Street forecast of $79.5 million. What about GeneDx's bottom line? The company posted a Q1 net loss of $6.5 million based on generally accepted accounting principles (GAAP). Ho ...

Financial Data and Key Metrics Changes - The company generated revenue of $665 million in Q1 2025, resulting in 4% organic growth, with a 1% headwind from foreign exchange [27][31] - Adjusted EPS for the quarter was $1.01, exceeding expectations of $0.93 to $0.95 [7][29] - Adjusted operating margins were reported at 25.6%, slightly up year-over-year and above expectations [28] Business Line Data and Key Metrics Changes - Life Sciences segment revenue was $340 million, up 1% reported and 2% organically, with low single-digit growth in pharma biotech customers and a decline in academic and government customers [32] - Diagnostics segment revenue reached $324 million, up 3% reported and 5% organically, driven by high single-digit growth in immunodiagnostics [33] Market Data and Key Metrics Changes - The Americas and Europe experienced mid-single-digit growth, while Asia saw low single-digit growth, with China also growing in low single digits [31] - U.S. academic customers, representing over 5% of total revenue, showed cautious spending due to uncertainties in funding [23][24] Company Strategy and Development Direction - The company is focused on maintaining strong organic growth and operational agility to navigate macroeconomic challenges [5][20] - A recent expanded alliance with Genomics England aims to enhance newborn genomic sequencing capabilities, positioning the company as a leader in this area [9] - The software business, representing about 8% of total revenue, grew over 20% organically in Q1 and is expected to continue strong growth [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's resilience and ability to adapt to changing market conditions, reaffirming a full-year adjusted EPS outlook of $4.9 to $5 [19][37] - The company anticipates a gross impact of approximately $135 million from tariffs, but expects to mitigate most of this through proactive measures [18][19] Other Important Information - The company repurchased $154 million of its shares in Q1, reducing the outstanding share count to 119.4 million [7][29] - The net debt to adjusted EBITDA leverage ratio was reported at 2.4 times, with all debt being fixed rate [30] Q&A Session Summary Question: Can you talk about the tariff impact and what products are affected? - Management indicated that they have been proactive in adjusting their supply chain to mitigate the $135 million gross tariff impact, focusing on products sold from the U.S. to China [41][43] Question: What are the expectations for the Life Sciences segment? - The Life Sciences segment is expected to see low single-digit growth, with instrumentation under pressure but solid growth in reagents [45][48] Question: How is the company managing its exposure in China? - The company expects low single-digit growth in China, with a slight decline in Life Sciences and mid-single-digit growth in Diagnostics [56] Question: What is the outlook for the software business? - The software business is expected to continue strong double-digit growth, with a focus on expanding into new markets [62][90] Question: What are the long-term margin expectations? - Long-term operating margin expectations remain unchanged, with a focus on SG&A volume leverage as growth continues [104]